

Case Report

[Open Access](#) [Case Report](#) PTZAID:IJICR-8-135

CNS-invasive aspergillosis following ibrutinib therapy

Published On: December 08, 2022 | Pages: 001 - 003

Author(s): Matthew Kurian*, Eric Vick and Dipen Khanapara

Ibrutinib is Bruton's tyrosine kinase inhibitor that now become the standard of care for the treatment of CLL (chronic lymphocytic leukemia) and other lymphoid cancers. With its increasing usage, oncologists must become more aware of their potential side effect profile. Ibrutinib is typically thought to be less immunosuppressive than standard immunotherapy; however, c ...

[Abstract View](#)

[Full Article View](#)

[DOI: 10.17352/2455-8591.000035](#)